Skip to main content

Table 1 Population baseline characteristics

From: Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

 

Total (n = 183)

Anti-CGRP mAbs (n = 86)

BoNT-A (n = 97)

p-value

Age, years, mean (SD)

46.1 (11.3)

45.9 (12.7)

46.3 (10.0)

0.8612

Sex, female, n (%)

155 (84.7)

67 (77.9)

88 (90.7)

0.023

Center, n (%)

   

< 0.001

 Milan

91 (49.7)

24 (27.9)

67 (69.1)

 

 Rome

92 (50.3)

62 (72.1)

30 (30.9)

 

Migraine duration, years, mean (SD)

28.4 (11.3)

27.6 (12.6)

29.1 (10.0)

0.3379

MOH, n (%)

146 (79.8)

66 (76.4)

80 (82.5)

0.361

TLS, n (%)

53 (29.0)

16 (18.6)

37 (38.1)

0.005

Comorbidities, n (%)

102 (55.7)

38 (44.2)

64 (66.0)

0.004

 Hypertension, n (%)

28 (15.3)

13 (15.1)

15 (15.5)

1.000

 Depression, n (%)

27 (14.8)

10 (11.6)

17 (17.5)

0.301

 Anxiety, n (%)

43 (23.5)

8 (9.3)

35 (36.1)

< 0.001

 Epilepsy, n (%)

1 (0.6)

1 (1.2)

0 (0.0)

0.470

 Cardiovascular, n (%)

7 (3.8)

2 (2.3)

5 (5.2)

0.450

 Gastroenteric, n (%)

10 (5.5)

6 (7.0)

4 (4.1)

0.519

 Chronic pain conditions, n (%)

4 (2.2)

2 (2.3)

2 (2.1)

1.000

 Cancer, n (%)

3 (1.64)

1 (1.2)

2 (2.1)

1.000

 Endocrine and metabolic, n (%)

11 (6.0)

7 (8.1)

4 (4.1)

0.353

 Other, n (%)

24 (13.1)

11 (12.8)

13 (13.4)

1.000

Concomitant migraine medications, n (%)

89 (48.9)

25 (29.1)

64 (66.7)

< 0.001

 Beta-blockers, n (%)

24 (13.1)

8 (9.3)

16 (16.5)

0.190

 TCA, n (%)

22 (12.0)

3 (3.5)

19 (19.6)

0.001

 Anti-Convulsant, n (%)

26 (14.2)

10 (11.6)

16 (16.5)

0.400

 ARBs, n (%)

16 (8.7)

4 (4.7)

12 (12.4)

0.072

 SSRI-SNRI, n (%)

31 (16.9)

11 (12.8)

20 (20.6)

0.173

 Pizotifen, n (%)

2 (1.09)

0 (0.0)

2 (2.06)

0.499

 SARI, n (%)

2 (1.09)

0 (0.0)

2 (2.06)

0.499

 Flunarizine, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

-

MHD, days, mean (SD)

20.3 (6.0)

18.7 (4.3)

21.7 (6.5)

0.0029

MIDAS, points, mean (SD)

88.1 (56.6)

84.6 (43.3)

91.3 (66.3)

0.7089

MAM, administrations, mean (SD)

20.9 (10.5)

18.6 (5.9)

22.9 (13.0)

0.1384

  1. Among comorbidities, Other include allergic asthma, amenorrhea, atopic dermatitis, autoimmune hepatitis, autoimmune thyroid disease, chronic vein insufficiency, connectivitis, essential tremor, Helicobacter pylori, hepatitis B infection, hepatitis C infection, hip dysplasia, insomnia, osteoarthritis, pituitary adenoma, polycystic ovary, psoriasis, reduction surgery of the jaw, restless leg syndrome, scleroderma, tuberculosis test positivity, upper airways resistance syndrome, and urticaria
  2. Abbreviations: ARBs Angiotensin receptor blockers, BoNT-A Onabotulinumtoxin-A, CGRP Calcitonin gene related peptide, mAbs Monoclonal antibodies, MAM Migraine acute medications, MHD Monthly headache days, MIDAS Migraine disability assessment test, MOH Medication overuse headache, SARI Serotonin antagonist and reuptake inhibitors, SD Standard deviation, SNRI Serotonin norepinephrine reuptake inhibitors, SSRI Selective serotonin reuptake inhibitors, TCA Tricyclic antidepressants, TLS Tension-like symptoms
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us